Grayscale Withdraws Cardano, Hedera, and Polkadot ETF Filings

Grayscale Withdraws Cardano, Hedera, and Polkadot ETF Filings

Grayscale withdrew registration statements for spot ETFs tracking Cardano, Hedera, and Polkadot within 190 seconds on Tuesday, offering no public explanation for the sudden retreat. Five other Grayscale altcoin ETF filings remain in preliminary status.

Aug 10, 2026, 03:01 AM1 min read

Published by CoinArticle’s AI-assisted newsroom · written from 1 cited source. How we work

Grayscale's Rapid Withdrawal

Grayscale withdrew its registration statements for spot ETFs tracking Cardano, Hedera, and Polkadot in rapid succession, according to SEC filings. The three withdrawals occurred within 190 seconds of each other. The company did not provide a reason for the action in the filings or any public statement.

Status of Other Filings

Five other Grayscale altcoin ETF applications remain on file in preliminary status, according to the SEC records. Those filings have not been withdrawn or approved. Grayscale has been actively pursuing spot ETF registrations across multiple alternative assets since the SEC's approval of the spot Bitcoin ETF in January 2024.

Context

The timing of the withdrawals raises questions about Grayscale's strategy in the altcoin ETF space. The company has positioned itself as a significant player in digital asset investment products, but regulatory approval for altcoin spot ETFs has proven more challenging than for Bitcoin or Ethereum. The lack of stated reasoning leaves the door open for the possibility of resubmission at a later date.

Why It Matters

For Traders

Spot ETF approval delays for major altcoins may reduce near-term institutional inflows, but do not preclude future filings or approvals.

For Investors

Grayscale's withdrawal signals either regulatory headwinds for altcoin ETFs or a shift in product priority, both relevant to institutional adoption timelines.

For Builders

The retreat suggests the SEC remains selective about which assets receive spot ETF treatment; protocols should monitor regulatory guidance rather than assume approval is inevitable.

This article is for information only and is not financial advice. Read the full disclaimer.

Related Articles

Latest News